Bruce D. Jackson
Stock Analyst at Benchmark
(3.90)
# 2,456
Out of 5,182 analysts
14
Total ratings
64.29%
Success rate
11.28%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Buy | $145 → $120 | $92.80 | +29.31% | 1 | Apr 17, 2026 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $21 → $15 | $7.23 | +107.47% | 2 | Apr 6, 2026 | |
| HUMA Humacyte | Downgrades: Speculative Buy | $10 → $1 | $0.81 | +24.08% | 3 | Mar 31, 2026 | |
| GNLX Genelux | Maintains: Speculative Buy | $23 → $20 | $2.56 | +681.25% | 1 | Mar 20, 2026 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $0.6 → $6 | $6.90 | -13.04% | 3 | Mar 16, 2026 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.34 | +194.12% | 1 | Nov 20, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $163.06 | -19.05% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $280 → $140 | $0.88 | +15,746.07% | 1 | Sep 15, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $6.06 | +411.55% | 1 | Sep 10, 2025 |
Abbott Laboratories
Apr 17, 2026
Maintains: Buy
Price Target: $145 → $120
Current: $92.80
Upside: +29.31%
Unicycive Therapeutics
Apr 6, 2026
Maintains: Speculative Buy
Price Target: $21 → $15
Current: $7.23
Upside: +107.47%
Humacyte
Mar 31, 2026
Downgrades: Speculative Buy
Price Target: $10 → $1
Current: $0.81
Upside: +24.08%
Genelux
Mar 20, 2026
Maintains: Speculative Buy
Price Target: $23 → $20
Current: $2.56
Upside: +681.25%
Harvard Bioscience
Mar 16, 2026
Maintains: Speculative Buy
Price Target: $0.6 → $6
Current: $6.90
Upside: -13.04%
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.34
Upside: +194.12%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $163.06
Upside: -19.05%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $280 → $140
Current: $0.88
Upside: +15,746.07%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $6.06
Upside: +411.55%